What was studied?
Healthy men underwent overnight blood sampling before exposure and again one week after receiving long-acting CJC-1295. The researchers examined pulse frequency, pulse magnitude and the lower concentrations between pulses.
What did the researchers report?
Growth-hormone pulsatility remained detectable. The main reported change was higher trough and mean hormone concentrations, rather than a change in pulse frequency or magnitude. This helps distinguish a larger overall hormone exposure from a different pulse pattern.
What are the limits?
This was a mechanistic hormone study in healthy men. It did not test improvements in physical function, recovery or longevity. The studied albumin-binding compound should not be treated as interchangeable with every product sold under a CJC-1295 label.
Original editorial summary by Sulan Peptide. Based on the source abstract; consult the full paper for methods, analyses, funding and disclosures.